Emergency Medicine Doctors in Palo Alto, CA Accepting Medicare

49 Emergency Medicine doctors found. Showing 41 - 49

Dr. Jennifer Tan Somsouk, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3801 Miranda Ave, Palo Alto, CA 94304 Phone: 650-493-5000

Dr. Derrick Lung, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1510 Page Mill Rd, Palo Alto, CA 94304 Phone: 415-643-3242

Jennifer Bauer, NP Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 795 El Camino Real, Palo Alto, CA 94301 Phone: 650-853-2958

Carlos Oscar Cruz, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 795 El Camino Real, Urgent Care , Palo Alto Center, Level 1, Lee Building, Palo Alto, CA 94301 Phone: 650-853-2958

Dr. Pravene A Nath, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 300 Pasteur Dr, H3200, M/c 5230, Palo Alto, CA 94305 Phone: 650-721-6408

Christopher Scott Evans, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3801 Miranda Ave, Palo Alto, CA 94304 Phone: 650-493-5000

Prof. Donald Adams Barr, M.D., PH.D., M.S. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 948 Ramona St, Palo Alto, CA 94301 Phone: 650-723-2884

Daniel Thomas Rogan, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 900 Welch Rd, Suite 350, Palo Alto, CA 94304 Phone: 650-724-0853

Jonathan Hootman, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 900 Quarry Road Extension, Palo Alto, CA 94304 Phone: 650-723-5111

News Archive

Breast cancer drug bevacizumab slows progression but has no overall survival benefit

The cancer drug bevacizumab (Avastin®) offers only a modest benefit in prolonging disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researchers. The researchers assessed the efficacy of bevacizumab in combination with chemotherapy, an established cancer treatment in this indication, and found no overall survival benefit when adding bevacizumab to chemotherapy.

New study estimates link between coffee consumption habits and incidence of mild cognitive impairment

A new study by researchers at the University of Bari Aldo Moro, Bari, Italy, Geriatric Unit & Laboratory of Gerontology and Geriatrics, IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Foggia, Italy, and Istituto Superiore di Sanità, Roma, Italy, estimates the association between change or constant habits in coffee consumption and the incidence of mild cognitive impairment (MCI), evaluating 1,445 individuals recruited from 5,632 subjects, aged 65-84 year old, from the Italian Longitudinal Study on Aging (ILSA), a population-based sample from eight Italian municipalities with a 3.5-year median follow-up.

New leukemia immune profiles predict drug resistance, positive responses to immunotherapy

By analyzing 442 samples from three groups of children and adults with acute myeloid leukemia (AML), researchers have identified new immune classes of the disease that predict the likelihood of drug resistance and positive responses to immunotherapy.

CTI BioPharma acquires worldwide rights to tosedostat

CTI BioPharma Corp. today announced that it has acquired worldwide rights to tosedostat through concurrent transactions with Vernalis R&D Limited, the originator of tosedostat, and Chroma Therapeutics Ltd., through which CTI previously held a sublicense with respect to tosedostat in North, Central and South America.

Read more Medical News

› Verified 2 days ago

• 1
• 2
• 3(current)